Compare Adaptive Biotechnologies Corp (ADPT) vs Equinor ASA (EQNR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Equinor ASA — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Equinor ASA trades at $34.31 (market cap $77.42B). The key difference: Equinor ASA is far larger — about 23.2× Adaptive Biotechnologies Corp's market cap, and Equinor ASA pays a 4.48% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EQNR | |
|---|---|---|
Market Cap | $3.33B | $77.42B |
Sector | Health | Energy |
52-Week High | $22.37 | $42.40 |
52-Week Low | $10.24 | $22.41 |
Enterprise Value | $3.19B | $89.19B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Equinor (EQNR) trades at $33.91, up 5.84% today, with a bearish technical signal despite recent earnings beats. The company shows solid cash flow from operations of $20.0B in 2025 and maintains a low EV/EBITDA of 2.21, but net income has declined to $5.04B. Recent strategic moves include acquiring BP's stake in Bay du Nord and expanding Norwegian gas production, while exiting non-core ventures like Japan offshore wind.
EQNR offers value with low valuation multiples and shareholder returns via dividends and buybacks, but faces risks from volatile energy prices and declining profitability. Analyst sentiment is mixed with 30% buy ratings, reflecting cautious optimism amid execution challenges and macroeconomic pressures on the oil and gas sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
